{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:29:47Z","timestamp":1787761787539,"version":"build-2784847793"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2021R1A6A1A03038899"],"award-info":[{"award-number":["NRF-2021R1A6A1A03038899"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ard.2025.12.002","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T12:22:14Z","timestamp":1767356534000},"page":"647-658","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment nonresponders in lupus nephritis characteristically exhibit persistent type I interferon signalling in monocytes: a longitudinal single-cell transcriptomic analysis"],"prefix":"10.1016","volume":"85","author":[{"given":"Woo-Joong","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-Soon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So-Young","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Bin","family":"Joo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Kyeong","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunsung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Yul","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woong-Yang","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eui-Cheol","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4658-1093","authenticated-orcid":false,"given":"Sang-Cheol","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ard.2025.12.002_bib0001","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/rheumatology\/kev311","article-title":"The frequency and outcome of lupus nephritis: results from an international inception cohort study","volume":"55","author":"Hanly","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.ard.2025.12.002_bib0002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10.1016\/j.ard.2025.12.002_bib0003","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41584-023-00925-5","article-title":"Treatment of lupus nephritis: consensus, evidence and perspectives","volume":"19","author":"Mok","year":"2023","journal-title":"Nat Rev Rheumatol"},{"issue":"1S","key":"10.1016\/j.ard.2025.12.002_bib0004","first-page":"S1","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ard.2025.12.002_bib0005","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-immunol-101921-042422","article-title":"Systemic lupus erythematosus pathogenesis: interferon and beyond","volume":"41","author":"Caielli","year":"2023","journal-title":"Annu Rev Immunol"},{"issue":"7","key":"10.1016\/j.ard.2025.12.002_bib0006","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/art.42849","article-title":"Standing on shoulders: interferon research from viral interference to lupus pathogenesis and treatment","volume":"76","author":"Crow","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.ard.2025.12.002_bib0007","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1136\/ard-2023-225445","article-title":"Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials","volume":"83","author":"Baker","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.12.002_bib0008","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13075-021-02414-0","article-title":"The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus","volume":"23","author":"Mai","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.ard.2025.12.002_bib0009","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13075-023-03010-0","article-title":"Relationship of systemic type I interferon activity with clinical phenotypes, disease activity, and damage accrual in systemic lupus erythematosus in treatment-naive patients: a retrospective longitudinal analysis","volume":"25","author":"Miyachi","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ard.2025.12.002_bib0010","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s42003-019-0382-x","article-title":"Gene expression analysis delineates the potential roles of multiple interferons in systemic lupus erythematosus","volume":"2","author":"Catalina","year":"2019","journal-title":"Commun Biol"},{"issue":"1","key":"10.1016\/j.ard.2025.12.002_bib0011","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000625","article-title":"Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis","volume":"9","author":"Northcott","year":"2022","journal-title":"Lupus Sci Med"},{"issue":"6","key":"10.1016\/j.ard.2025.12.002_bib0012","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard-2022-223628","article-title":"2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice","volume":"82","author":"Rodriguez-Carrio","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"23","key":"10.1016\/j.ard.2025.12.002_bib0013","doi-asserted-by":"crossref","first-page":"9373","DOI":"10.1073\/pnas.0903487106","article-title":"Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes","volume":"106","author":"Cheon","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"10.1016\/j.ard.2025.12.002_bib0014","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1038\/emboj.2013.203","article-title":"IFNbeta-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage","volume":"32","author":"Cheon","year":"2013","journal-title":"EMBO J"},{"issue":"3","key":"10.1016\/j.ard.2025.12.002_bib0015","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/s12276-023-00964-8","article-title":"Corticosteroids reduce pathologic interferon responses by downregulating STAT1 in patients with high-risk COVID-19","volume":"55","author":"Jeong","year":"2023","journal-title":"Exp Mol Med"},{"issue":"7","key":"10.1016\/j.ard.2025.12.002_bib0016","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/s41590-019-0398-x","article-title":"The immune cell landscape in kidneys of patients with lupus nephritis","volume":"20","author":"Arazi","year":"2019","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.ard.2025.12.002_bib0017","doi-asserted-by":"crossref","first-page":"223","DOI":"10.4078\/jrd.22.0006","article-title":"Predictive factors for renal response in lupus nephritis: a single-center prospective cohort study","volume":"29","author":"Park","year":"2022","journal-title":"J Rheum Dis"},{"issue":"8","key":"10.1016\/j.ard.2025.12.002_bib0018","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.ard.2025.12.002_bib0019","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2025.12.002_bib0020","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"11","key":"10.1016\/j.ard.2025.12.002_bib0021","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","article-title":"Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis","volume":"71","author":"Bertsias","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2025.12.002_bib0022","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/1756-185X.12212","article-title":"Overview of lupus nephritis management guidelines and perspective from Asia","volume":"16","author":"Mok","year":"2013","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2025.12.002_bib0023","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2025.12.002_bib0024","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.ard.2025.12.002_bib0025","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","article-title":"Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices","volume":"93","author":"Bajema","year":"2018","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.ard.2025.12.002_bib0026","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/art.21625","article-title":"The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials","volume":"54","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.ard.2025.12.002_bib0027","first-page":"139","article-title":"KDIGO Clinical Practice Guideline for Glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"33","key":"10.1016\/j.ard.2025.12.002_bib0028","doi-asserted-by":"crossref","first-page":"10443","DOI":"10.1073\/pnas.1513341112","article-title":"Roles of unphosphorylated ISGF3 in HCV infection and interferon responsiveness","volume":"112","author":"Sung","year":"2015","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"7","key":"10.1016\/j.ard.2025.12.002_bib0029","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/j.1742-4658.2006.05176.x","article-title":"Identification of GAS-dependent interferon-sensitive target genes whose transcription is STAT2-dependent but ISGF3-independent","volume":"273","author":"Brierley","year":"2006","journal-title":"FEBS J"},{"issue":"7","key":"10.1016\/j.ard.2025.12.002_bib0030","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.4049\/jimmunol.177.7.4530","article-title":"STAT1-independent cell type-specific regulation of antiviral APOBEC3G by IFN-alpha","volume":"177","author":"Sarkis","year":"2006","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.ard.2025.12.002_bib0031","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1158\/0008-5472.CAN-08-4922","article-title":"IRF-9\/STAT2 [corrected] functional interaction drives retinoic acid-induced gene G expression independently of STAT1","volume":"69","author":"Lou","year":"2009","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.ard.2025.12.002_bib0032","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1042\/BJ20140644","article-title":"STAT2\/IRF9 directs a prolonged ISGF3-like transcriptional response and antiviral activity in the absence of STAT1","volume":"466","author":"Blaszczyk","year":"2015","journal-title":"Biochem J"},{"issue":"12","key":"10.1016\/j.ard.2025.12.002_bib0033","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1002\/art.20798","article-title":"Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus","volume":"50","author":"Kirou","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.ard.2025.12.002_bib0034","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.4049\/jimmunol.1001359","article-title":"A novel role for IFN-stimulated gene factor 3II in IFN-gamma signaling and induction of antiviral activity in human cells","volume":"186","author":"Morrow","year":"2011","journal-title":"J Immunol"},{"issue":"43","key":"10.1016\/j.ard.2025.12.002_bib0035","doi-asserted-by":"crossref","first-page":"17609","DOI":"10.1073\/pnas.1209724109","article-title":"Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases","volume":"109","author":"Hall","year":"2012","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"10","key":"10.1016\/j.ard.2025.12.002_bib0036","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ni.3818","article-title":"Type I interferons and the cytokine TNF cooperatively reprogram the macrophage epigenome to promote inflammatory activation","volume":"18","author":"Park","year":"2017","journal-title":"Nat Immunol"},{"issue":"8","key":"10.1016\/j.ard.2025.12.002_bib0037","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/art.40476","article-title":"Development of a molecular signature to monitor pharmacodynamic responses mediated by in vivo administration of glucocorticoids","volume":"70","author":"Hu","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.ard.2025.12.002_bib0038","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2665-9913(21)00006-0","article-title":"Glucocorticoid gene signatures in systemic lupus erythematosus and the effects of type I interferon: a cross-sectional and in-vitro study","volume":"3","author":"Northcott","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"10.1016\/j.ard.2025.12.002_bib0039","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.ekir.2024.03.014","article-title":"Interferon and B-cell signatures inform precision medicine in lupus nephritis","volume":"9","author":"Parodis","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"11","key":"10.1016\/j.ard.2025.12.002_bib0040","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.immuni.2024.09.004","article-title":"Type I IFN drives unconventional IL-1beta secretion in lupus monocytes","volume":"57","author":"Caielli","year":"2024","journal-title":"Immunity"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725045960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725045960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T08:20:07Z","timestamp":1780820407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725045960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0003496725045960"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.12.002","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment nonresponders in lupus nephritis characteristically exhibit persistent type I interferon signalling in monocytes: a longitudinal single-cell transcriptomic analysis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Alliance of Associations for Rheumatology (EULAR). Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}